Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Gross Margin (2016 - 2025)

Bioadaptives' Gross Margin history spans 7 years, with the latest figure at 72.72% for Q4 2025.

  • On a quarterly basis, Gross Margin changed N/A to 72.72% in Q4 2025 year-over-year; TTM through Dec 2025 was 68.37%, a 3656.0% increase, with the full-year FY2025 number at 68.37%, up 3656.0% from a year prior.
  • Gross Margin hit 72.72% in Q4 2025 for Bioadaptives, down from 83.14% in the prior quarter.
  • Over the last five years, Gross Margin for BDPT hit a ceiling of 83.14% in Q3 2025 and a floor of 25.85% in Q4 2022.
  • Historically, Gross Margin has averaged 49.48% across 5 years, with a median of 55.25% in 2021.
  • Biggest five-year swings in Gross Margin: soared 5107bps in 2021 and later plummeted -3053bps in 2025.
  • Tracing BDPT's Gross Margin over 5 years: stood at 29.65% in 2021, then dropped by -13bps to 25.85% in 2022, then soared by 45bps to 37.48% in 2023, then surged by 70bps to 63.56% in 2024, then grew by 14bps to 72.72% in 2025.
  • Business Quant data shows Gross Margin for BDPT at 72.72% in Q4 2025, 83.14% in Q3 2025, and 33.02% in Q2 2025.